← SynDRA
BARICITINIB
SynDRA canonical compound SYN0031618 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx |
|---|
| Primary target(s) | JAK2 |
|---|
| Mechanism of action | JAK inhibitor |
|---|
| Indication | rheumatoid arthritis |
|---|
| Disease area | rheumatology |
|---|
All known targets
- JAK2
- JAK1
- AAK1
- GAK
- TYK2
- BMP2K
- JAK3
- PRKCA
- PRKCB
- PRKCD
- PKN2
- RET
Mechanisms of action (all sources)
- JAK inhibitor
- JAK1 INHIBITOR
- Tyrosine-protein kinase JAK1 inhibitor
- JAK2 INHIBITOR
- Tyrosine-protein kinase JAK2 inhibitor
- AAK1 INHIBITOR
- BMP2K INHIBITOR
- GAK INHIBITOR
- JAK3 INHIBITOR
- TYK2 INHIBITOR
- JAK2 MODULATOR
- JAK1 MODULATOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- YJ005
- STAT3
- SYK
- NQO2
- PAK2
- PAICS
- OPRM1
- OPA1
- OLA1
- NUAK2
- NLK
- MYLK
- NEK9
- NEK3
- NEK2
- NEK1
- NDUFA13
- NAT10
- PAK4
- PAK6
- PASK
- PDE3A
- PRKACG
- PRKACB
- PRKAA1
- PLK4
- PKMYT1
- PIP4K2C
- PIM1
- PHKG2
- PGRMC1
- PGR
- PFKP
- PEBP1
- PDXK
- PDGFRB
- PDE4A
- MYLK3
- MYH10
- MYH14
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- GPX4
- HLA-B
- HLAB
- HTT
- IFNB1
- KSYK
- NSD2
Drug classes
- Janus Kinase Inhibitors
- Janus Kinase Inhibitor
ATC classes
- L04A · IMMUNOSUPPRESSANTS
Cross-references
Synonyms
- OLUMIANT
- Olumiant
- LY3009104
- INCB028050
- olumiant
- BARICITINIB PHOSPHATE
- BARICITINIB PHOSPHATE SALT
- INCB-28050
- 3JW
- BARICITINIB (INCB028050)
- BARICITINIB (LY3009104)
- INCB-028050
- LY-3009104
- Baricitinib (LY3009104, INCB028050)
- Baricitinib [USAN:INN]
- C16H17N7O2S
- ISP4442I3Y
- J-503551
- Olumiant (TN)
- UNII-ISP4442I3Y
- LY 3009104
- LY3009104 (phosphate);INCB028050 (phosphate)
- INCB28050
- Baricitinib [USAN]
- INCB 28050
- BARICITINIB [MI]
- BARICITINIB [INN]
- BARICITINIB [JAN]
- BARICITINIB [WHO-DD]
- MLS006011247
- SCHEMBL871150
- Baricitinib (JAN/USAN/INN)
- Baricitinib (LY3009104)
- BARICITINIB [EMA EPAR]
- Baricitinib (INCB028050)
- GTPL7792
- CHEMBL2105759
Reported adverse events
- Lymphoma
- TB
- Thrombosis
- Active tuberculosis
- Acne
- Folliculitis
- Headache
- Infection
- Nausea
- Thrombocytosis
- Abdominal pain
- Alopecia
Look up BARICITINIB in the interactive SynDRA portal →